Yahoo Finance

Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool

SALT LAKE CITY, May 29, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today published in Nature Genetics ...
Mena FN

Power Of Recursion OS On Display At Genome Scale In Nature Genetics Paper Detailing Potential Limitation Of CRISPR Gene Editing Tool

(MENAFN- GlobeNewsWire - Nasdaq) Published open-access today in Nature Genetics,“High-resolution genome-wide mapping of chromosome-arm-scale truncations induced by CRISPR–Cas9 editing” identifies ...

Forget Recursion Pharmaceuticals stock. This is a much better buy.

Eli Lilly is a safer way to capitalize on AI-driven drug discovery.
The Globe and Mail

Recursion Pharmaceuticals Wants to 4X Its Supercomputing Power for AI With the Help of Nvidia. Here's Why It Matters.

For a biotech like Recursion Pharmaceuticals (NASDAQ: RXRX) that aims to use artificial intelligence (AI) and petabytes of data as tools for drug discovery and development, computing power is a key ...
FierceBiotech

After a tough year, Exscientia folds into Recursion to create an AI superpower

After a year defined by pipeline cuts, the departure of its CEO and layoffs, Exscientia will merge into Recursion, creating one company that has 10 clinical readouts to look forward to over the next ...
The Motley Fool

Recursion Pharmaceuticals Wants to 4X Its Supercomputing Power for AI With the Help of Nvidia. Here's Why It Matters.

Nvidia will help Recursion build a massive supercomputer. This will be used its for AI-driven drug discovery efforts. It may be the first of several moves to empower its platform. With the help of its ...